A. Dorsey, MD, S. Ahmed, MD, J. M Morton, MD, MPH, FACS, FASMBS. Stanford
INTRODUCTION: The Reshape ® intra-gastric balloon is a saline-filled dual chamber intra-gastric balloon approved by the FDA for weight loss in patients with BMI of 30-40 mg/kg2 who otherwise failed to lose weight with diet and exercise. The intra-gastric balloon promotes weight loss by reducing gastric capacity and enhancing satiety. The aim of this paper is to determine the weight loss attained at 3, 6, and 12 months with the intra-gastric balloon among BMI ranges.
METHODS: At a single academic center, preoperative, 3 month, 6 month, and 12 month data were prospectively collected from individuals undergoing ReShape® Intra-gastric Balloon placement. Patients were categorized into BMI 30-34.9 (Stage 1), 35-39.9 (Stage 2), and >40 (Stage 3). Data were analyzed with Student T tests, ANOVAs and Chi square tests.
RESULTS: Forty six patients underwent placement and subsequent removal of the intra-gastric balloon from 2015 – 2018. Sixty five percent of patients were women. Mean age at placement was 48 yrs, mean weight and BMI at placement were 344 lbs and 38 kg/m2. Seventy eight percent of patients were on pre-operative weight loss medications, which included Lomaira, Contrave, Saxenda, and Metformin. There were no differences in percentage of patients with preoperative diabetes (Stage 1-12% vs Stage 2- 6% vs Stage 3- 9%, p=0.8), hyperlipidemia (17% vs 12% vs 45%, p=0.09) or OSA (18% vs 29% vs 36%, p=0.5). Mean duration of balloon use was 6.5 months. All stages of obesity had significant weight loss: Stage 1 BMI pre-op, 3, 6, 12 mo: 32.4, 29.2, 28.6, 28.7 (p<0.01); Stage 2, BMI pre-op, 3, 6, 12 mo: 37.5, 33.5, 32.2, 31.5 (p<0.01); Stage 3 BMI pre-op, 3, 6 mo: 48.1, 43.1, 41.3, 40.3 (p<0.01). Stage 1 had the greatest % excess weight loss (%EWL) at 3 and 6 months (3 mo: Stage 1-61% vs Stage-2 39% vs Stage 3-24%, p<0.01; 6 mo: 71% vs 51% vs 33%, p<0.01). No difference in %EWL at 12 mo (60% vs 58% vs 40% (p=0.5). All groups had similar percent decrease in BMI (3 mo: Stage 1- 10% vs Stage 2- 11% vs Stage 3-10%, p=0.7; 6 mo: 11% vs 14% vs 14%, p=0.5; 12 mo: 10% vs 16% vs 16%, p=0.2).
CONCLUSIONS: Our study shows significant weight loss following intra-gastric balloon placement among all stages. Weight loss was sustained even after balloon removal.
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 95578
Program Number: P062
Presentation Session: Poster Session (Non CME)
Presentation Type: Poster
sages_adbutler_leaderboard